WallStSmart

Insmed Inc (INSM)vsSarepta Therapeutics Inc (SRPT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sarepta Therapeutics Inc generates 262% more annual revenue ($2.20B vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -32.5%. INSM appears more attractively valued with a PEG of 1.09. SRPT earns a higher WallStSmart Score of 45/100 (D).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

SRPT

Hold

45

out of 100

Grade: D

Growth: 7.3Profit: 2.0Value: 4.0Quality: 6.0
Piotroski: 2/9Altman Z: -0.42

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

SRPT2 strengths · Avg: 9.0/10
EPS GrowthGrowth
2664.0%10/10

Earnings expanding 2664.0% YoY

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

SRPT4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
159.252/10

Expensive relative to growth rate

Return on EquityProfitability
-53.5%2/10

ROE of -53.5% — below average capital efficiency

Revenue GrowthGrowth
-32.7%2/10

Revenue declined 32.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : SRPT

The strongest argument for SRPT centers on EPS Growth, Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : SRPT

The primary concerns for SRPT are Piotroski F-Score, PEG Ratio, Return on Equity.

Key Dynamics to Monitor

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

SRPT generates stronger free cash flow (125M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SRPT scores higher overall (45/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Sarepta Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?